BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
59.61
+0.50 (0.85%)
Jul 21, 2026, 10:26 AM EDT - Market open
BioMarin Pharmaceutical Employees
BioMarin Pharmaceutical had 3,221 employees as of December 31, 2025. The number of employees increased by 181 or 5.95% compared to the previous year.
Employees
3,221
Change (1Y)
181
Growth (1Y)
5.95%
Revenue / Employee
$1,006,618
Profits / Employee
$83,434
Market Cap
11.52B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 3,221 | 181 | 5.95% |
| Dec 31, 2024 | 3,040 | -361 | -10.61% |
| Dec 31, 2023 | 3,401 | 319 | 10.35% |
| Dec 31, 2022 | 3,082 | 37 | 1.22% |
| Dec 31, 2021 | 3,045 | -14 | -0.46% |
| Dec 31, 2020 | 3,059 | 58 | 1.93% |
| Dec 31, 2019 | 3,001 | 152 | 5.34% |
| Dec 31, 2018 | 2,849 | 268 | 10.38% |
| Dec 31, 2017 | 2,581 | 288 | 12.56% |
| Dec 31, 2016 | 2,293 | 135 | 6.26% |
| Dec 31, 2015 | 2,158 | 477 | 28.38% |
| Dec 31, 2014 | 1,681 | 340 | 25.35% |
| Dec 31, 2013 | 1,341 | 252 | 23.14% |
| Dec 31, 2012 | 1,089 | 87 | 8.68% |
| Dec 31, 2011 | 1,002 | 131 | 15.04% |
| Dec 31, 2010 | 871 | 151 | 20.97% |
| Dec 31, 2009 | 720 | 71 | 10.94% |
| Dec 31, 2008 | 649 | 124 | 23.62% |
| Dec 31, 2007 | 525 | 115 | 28.05% |
| Dec 31, 2006 | 410 | 96 | 30.57% |
| Dec 31, 2005 | 314 | -45 | -12.53% |
| Dec 31, 2004 | 359 | 87 | 31.99% |
| Dec 31, 2003 | 272 | 53 | 24.20% |
| Dec 31, 2002 | 219 | 3 | 1.39% |
| Dec 31, 2001 | 216 | 42 | 24.14% |
| Dec 31, 2000 | 174 | 25 | 16.78% |
| Dec 31, 1999 | 149 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| Axsome Therapeutics | 1,220 |
| Madrigal Pharmaceuticals | 915 |
| Corcept Therapeutics | 730 |
| Arrowhead Pharmaceuticals | 711 |
| Cytokinetics | 673 |
| Krystal Biotech | 295 |
| Summit Therapeutics | 265 |
BMRN News
- 5 days ago - BioMarin price target raised to $76 from $75 at Citi - TheFly
- 8 days ago - BioMarin announces FDA accepts sNDA for full approval of Voxzogo - TheFly
- 8 days ago - U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia - PRNewsWire
- 14 days ago - BioMarin price target lowered to $62 from $66 at RBC Capital - TheFly
- 5 weeks ago - BioMarin’s Voxzogo and BMN 333 show impact in hypochondroplasia, achondroplasia - TheFly
- 5 weeks ago - BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026 - PRNewsWire
- 6 weeks ago - Ascendis Pharma ‘oversold’ following ITC development, says Oppenheimer - TheFly
- 6 weeks ago - BioMarin Pharmaceutical Transcript: AGM 2026 - Transcripts